化学
药物发现
化学空间
高通量筛选
药品
小分子
比例(比率)
吞吐量
机器学习
计算生物学
数据挖掘
药理学
计算机科学
生物化学
医学
量子力学
电信
生物
物理
无线
作者
Alex T. Müller,Markus Hierl,Dominik Heer,Paul Westwood,Philippe Hartz,Bigna Wörsdörfer,Christian Krämer,Wolfgang Haap,Doris Roth,Michael Reutlinger
标识
DOI:10.1021/acs.jmedchem.5c00943
摘要
High-throughput screening (HTS) remains central to small molecule lead discovery, but increasing assay complexity challenges the screening of large compound libraries. While retrospective studies have assessed active-learning-guided screening, extensive prospective validations are rare. Here, we report the first prospective evaluation of machine learning (ML)-assisted iterative HTS in a large-scale drug discovery project. Using a mass spectrometry-based assay for salt-inducible kinase 2, we screened just 5.9% of a two million-compound library in three batches and recovered 43.3% of all primary actives identified in a parallel full HTS─including all but one compound series selected by medicinal chemists. This demonstrates that ML-guided iterative screening can significantly reduce the experimental cost while maintaining hit discovery quality. Retrospective benchmarks further showed that the ML approach outperforms similarity-based methods in hit recovery and chemical space coverage. In summary, this study highlights the potential of ML-driven iterative HTS to improve efficiency also in large-scale drug discovery projects.
科研通智能强力驱动
Strongly Powered by AbleSci AI